Literature DB >> 3437071

Pharmacokinetics of moxonidine after single and repeated daily doses in healthy volunteers.

D Trenk1, F Wagner, E Jähnchen, V Plänitz.   

Abstract

The pharmacokinetics of the centrally acting alpha-2 agonist moxonidine were investigated in 12 healthy male subjects after single and repeated oral doses (q12h for five days) of moxonidine 0.2 mg. Plasma concentration-time data followed the general characteristics of a one-compartment model with first-order absorption. Peak plasma concentrations of 1.29 +/- 0.32 ng/mL were achieved 0.74 +/- 0.35 hours after ingestion of a 0.2-mg tablet. The terminal half-life of elimination was 2.12 +/- 0.58 hours. The oral clearance (CL/F) amounted to 830 +/- 171 mL/min with renal elimination being the major route of elimination. No significant differences in pharmacokinetic parameters could be observed following repeated dosing over five days.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3437071     DOI: 10.1002/j.1552-4604.1987.tb05602.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  13 in total

1.  Lack of pharmacokinetic interaction between moxonidine and hydrochlorothiazide.

Authors:  H J Weimann; G Pabst; W Weber
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Lack of pharmacokinetic interactions between moxonidine and digoxin.

Authors:  G Pabst; H J Weimann; W Weber
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

3.  A comparison of the haemodynamic and behavioural effects of moxonidine and clonidine in normotensive subjects.

Authors:  G J Macphee; C A Howie; H L Elliott; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1992-03       Impact factor: 4.335

Review 4.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

5.  Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.

Authors:  M O Karlsson; E N Jonsson; C G Wiltse; J R Wade
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

6.  The influence of renal function on clinical pharmacokinetics of moxonidine.

Authors:  W Kirch; H J Hutt; V Plänitz
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

7.  Steady state investigation of possible pharmacokinetic interactions of moxonidine and glibenclamide.

Authors:  M Müller; H J Weimann; G Eden; W Weber; K Michaelis; C Dilger; G Achtert
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1993 Jul-Sep       Impact factor: 2.441

8.  The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress.

Authors:  René R Wenzel; Anna Mitchell; Winfried Siffert; Sandra Bührmann; Thomas Philipp; Rafael F Schäfers
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

9.  Absolute bioavailability of moxonidine.

Authors:  R Theodor; H J Weimann; W Weber; K Michaelis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Apr-Jun       Impact factor: 2.441

Review 10.  Moxonidine. A review of its pharmacology, and therapeutic use in essential hypertension.

Authors:  P Chrisp; D Faulds
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.